Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 6/20 | 0.37 |
| ▸ | MLLT1 | Q03111 | 4/20 | 0.36 |
| ▸ | F2 | P00734 | 4/20 | 0.35 |
| ▸ | F10 | P00742 | 3/20 | 0.34 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.34 |
| ▸ | F9 | P00740 | 2/20 | 0.34 |
| ▸ | F7 | P08709 | 1/20 | 0.34 |
| ▸ | KLK1 | P06870 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7068332 | 0.81 | F2 (0.40) | MLLT1F2F9 | |
| SCHEMBL7067672 | 0.78 | MLLT1 (0.41) | MLLT1F2F10KLK5F9 | |
| SCHEMBL7069160 | 0.78 | MAPT (0.44) | MLLT1F2TSHRMAPK10 | |
| SCHEMBL7072410 | 0.77 | MAPT (0.43) | TSHRMAPK10 | |
| SCHEMBL7072413 | 0.76 | MAPT (0.43) | F10TSHRMAPK10 | |
| SCHEMBL7071781 | 0.75 | F10 (0.42) | F10 | |
| SCHEMBL7071866 | 0.74 | MLLT1 (0.36) | MLLT1F9TSHR | |
| SCHEMBL7071907 | 0.72 | NOD1 (0.38) | ACSS2MLLT1F9TSHR | |
| SCHEMBL7364157 | 0.72 | MAPT (0.42) | F9 | |
| SCHEMBL7072014 | 0.71 | ACSS2 (0.39) | ACSS2F9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | AXYS PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | US | disclosed |
| US-6562854-B2 | Antiinflammatory agents; respiratory system disorders | AXYS PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | Celera Corporation | 2001-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | CMA1, CPA3, TPSG1 | ACSS2 609/4885MLLT1 4411/4885F2 1732/4885 |
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | CMA1, TPSG1, TPSD1 | ACSS2 746/4885MLLT1 3937/4885F2 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.